These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 27217070)

  • 1. Racial disparities in the risk of Stevens-Johnson Syndrome and toxic epidermal necrolysis as urate-lowering drug adverse events in the United States.
    Lu N; Rai SK; Terkeltaub R; Kim SC; Menendez ME; Choi HK
    Semin Arthritis Rheum; 2016 Oct; 46(2):253-258. PubMed ID: 27217070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population.
    Tassaneeyakul W; Jantararoungtong T; Chen P; Lin PY; Tiamkao S; Khunarkornsiri U; Chucherd P; Konyoung P; Vannaprasaht S; Choonhakarn C; Pisuttimarn P; Sangviroon A; Tassaneeyakul W
    Pharmacogenet Genomics; 2009 Sep; 19(9):704-9. PubMed ID: 19696695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost-effectiveness of HLA-B*5801 screening to guide initial urate-lowering therapy for gout in the United States.
    Jutkowitz E; Dubreuil M; Lu N; Kuntz KM; Choi HK
    Semin Arthritis Rheum; 2017 Apr; 46(5):594-600. PubMed ID: 27916277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel.
    Halevy S; Ghislain PD; Mockenhaupt M; Fagot JP; Bouwes Bavinck JN; Sidoroff A; Naldi L; Dunant A; Viboud C; Roujeau JC;
    J Am Acad Dermatol; 2008 Jan; 58(1):25-32. PubMed ID: 17919772
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Ponzo MG; Miliszewski M; Kirchhof MG; Keown PA; Dutz JP
    J Cutan Med Surg; 2019; 23(6):595-601. PubMed ID: 31378082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HLA-B*58:01 is a risk factor for allopurinol-induced DRESS and Stevens-Johnson syndrome/toxic epidermal necrolysis in a Portuguese population.
    Gonçalo M; Coutinho I; Teixeira V; Gameiro AR; Brites MM; Nunes R; Martinho A
    Br J Dermatol; 2013 Sep; 169(3):660-5. PubMed ID: 23600531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of human leukocyte antigen variants and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: A meta-analysis.
    Li X; Zhao Z; Sun SS
    Am J Health Syst Pharm; 2017 May; 74(9):e183-e192. PubMed ID: 28438823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: An Analysis of Triggers and Implications for Improving Prevention.
    Miliszewski MA; Kirchhof MG; Sikora S; Papp A; Dutz JP
    Am J Med; 2016 Nov; 129(11):1221-1225. PubMed ID: 27086495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic utility of HLA-B*5801 screening in severe allopurinol hypersensitivity syndrome: an updated systematic review and meta-analysis.
    Yu KH; Yu CY; Fang YF
    Int J Rheum Dis; 2017 Sep; 20(9):1057-1071. PubMed ID: 28857441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of Ocular Manifestation and Genetic Association of Allopurinol-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in South Korea.
    Lee HS; Ueta M; Kim MK; Seo KY; Sotozono C; Kinoshita S; Yoon KC
    Cornea; 2016 Feb; 35(2):199-204. PubMed ID: 26655481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allopurinol-Induced Stevens-Johnson Syndrome.
    Gupta SS; Sabharwal N; Patti R; Kupfer Y
    Am J Med Sci; 2019 Apr; 357(4):348-351. PubMed ID: 30638600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of Stevens-Johnson syndrome following combination drug use of allopurinol, carbamazepine and phenytoin in Taiwan: A case-control study.
    Syu FK; Pan HY; Chuang PC; Huang YS; Cheng CY; Cheng FJ
    J Dermatol; 2018 Sep; 45(9):1080-1087. PubMed ID: 29963717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective study of 213 cases of Stevens-Johnson syndrome and toxic epidermal necrolysis from China.
    Yang L; Shou YH; Li F; Zhu XH; Yang YS; Xu JH
    Burns; 2020 Jun; 46(4):959-969. PubMed ID: 31898979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of HLA-B*58: 01 genetic testing before initiation of allopurinol therapy to prevent allopurinol-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in a Malaysian population.
    Chong HY; Lim YH; Prawjaeng J; Tassaneeyakul W; Mohamed Z; Chaiyakunapruk N
    Pharmacogenet Genomics; 2018 Feb; 28(2):56-67. PubMed ID: 29176400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of toxic epidermal necrolysis by a multidisciplinary team. A review of literature and treatment results.
    Papp A; Sikora S; Evans M; Song D; Kirchhof M; Miliszewski M; Dutz J
    Burns; 2018 Jun; 44(4):807-815. PubMed ID: 29627131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Kaniwa N; Saito Y; Aihara M; Matsunaga K; Tohkin M; Kurose K; Sawada J; Furuya H; Takahashi Y; Muramatsu M; Kinoshita S; Abe M; Ikeda H; Kashiwagi M; Song Y; Ueta M; Sotozono C; Ikezawa Z; Hasegawa R;
    Pharmacogenomics; 2008 Nov; 9(11):1617-22. PubMed ID: 19018717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of genotyping for HLA-B*5801 and an enhanced safety program in gout patients starting allopurinol in Singapore.
    Dong D; Tan-Koi WC; Teng GG; Finkelstein E; Sung C
    Pharmacogenomics; 2015 Nov; 16(16):1781-93. PubMed ID: 26554739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of Stevens-Johnson syndrome/toxic epidermal necrolysis among new users of different individual drugs in a European population: a case-population study.
    Rodríguez-Martín S; Martín-Merino E; Lerma V; Rodríguez-Miguel A; González O; González-Herrada C; Ramírez E; Bellón T; de Abajo FJ
    Eur J Clin Pharmacol; 2019 Feb; 75(2):237-246. PubMed ID: 30298362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence, causative factors and mortality rates of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in northern Italy: data from the REACT registry.
    Diphoorn J; Cazzaniga S; Gamba C; Schroeder J; Citterio A; Rivolta AL; Vighi GD; Naldi L;
    Pharmacoepidemiol Drug Saf; 2016 Feb; 25(2):196-203. PubMed ID: 26687641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of HLA-B*5801 allele and allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis.
    Somkrua R; Eickman EE; Saokaew S; Lohitnavy M; Chaiyakunapruk N
    BMC Med Genet; 2011 Sep; 12():118. PubMed ID: 21906289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.